APAC Diabetic Retinopathy Market

APAC Diabetic Retinopathy Market Size 

The apac diabetic retinopathy market size was valued at USD 1.94 billion in 2024. The apac diabetic retinopathy market size is expected to have 7.94 % CAGR from 2025 to 2033 and be worth USD 3.86 billion by 2033 from USD 2.09 billion in 2025.  

Asia is predicted to show wealthy growth in the forecast period. Within the Asian region, the western pacific region accounts for a larger share of blindness due to DR when equated to South-East Asia. The primary factor contributing to the increasing share of Diabetic Retinopathy among the growing economies is a vast pool of patients and increasing support and funding given by the government.

Diabetic retinopathy is considered a severe sight-threatening problem that results due to chronic diabetes. The treatment for diabetic retinopathy may require intraocular injections, anti-VEGF drugs, laser surgery, or vitrectomy, depending on the severity of the condition.

The rapidly expanding diabetic population coupled with increasing awareness of diabetic retinopathy is expected to drive the global diabetic retinopathy drug market in the coming years. In addition, rising medical procedures due to the high penetration of medical insurance and increasing government initiatives to prevent diabetes-related risks is also believed to garner the growth of the retinopathy drug market in the future.

REGIONAL ANALYSIS 

The Asia Pacific diabetic retinopathy market is expected to register the highest CAGR among all the regions in the global market during the forecast period and is mainly driven by the low-income population, lack of skilled professionals, and poor access to healthcare facilities. Emerging economies such as Japan and China are expected to boost the APAC market to achieve the new growth heights during the forecast period due to their growth in disposable income, rise in the aging population, increasing funding for diabetes research, diagnostic innovations, and large target populations. The Chinese diabetic retinopathy market is anticipated to achieve rapid growth during the forecast period. The Japanese diabetic retinopathy market is the largest in Asia-Pacific due to high medical costs and increasing disposable income. Also, increased use of Lucentis is foreseen to drive market growth in the area.

KEY MARKET PLAYERS

A few prominent companies in the APAC Diabetic Retinopathy Market profiled in the report are Bayer AG, Pfizer Inc., Hoffmann-La Roche Ltd., Regeneron Pharmaceutical Inc., Novartis AG, Valeant Pharmaceutical International Inc., Abbott Laboratories Inc., Alimera Science Inc., and Ampio Pharmaceuticals Inc.

MARKET  SEGMENTATION

This research report on the APAC diabetic retinopathy market has been segmented and sub-segmented into the following categories

By Treatment Type

• Anti-Vascular Endothelial Growth Factor (VEGF) drug
• Intraocular Steroid Injection
• Laser Surgery
• Vitrectomy     

By Indication

• Non-Proliferative Diabetic Retinopathy (NPDR)
  • Mild
  • Moderate
  • Severe
• Proliferative Diabetic Retinopathy (PDR) 

By End-User

• Hospitals
• Ophthalmic Clinics
• Ambulatory Surgical Centers

By Country

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC